These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 22860921)

  • 1. Waldenström macroglobulinemia: my way.
    Gertz M
    Leuk Lymphoma; 2013 Mar; 54(3):464-71. PubMed ID: 22860921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Waldenström macroglobulinemia.
    Gertz MA
    Hematology; 2012 Apr; 17 Suppl 1():S112-6. PubMed ID: 22507796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Waldenström macroglobulinemia: 2015 update on diagnosis, risk stratification, and management.
    Gertz MA
    Am J Hematol; 2015 Apr; 90(4):346-54. PubMed ID: 25808108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Waldenström macroglobulinemia: 2011 update on diagnosis, risk stratification, and management.
    Gertz MA
    Am J Hematol; 2011 May; 86(5):411-6. PubMed ID: 21523800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Changes in the prognosis and treatment of Waldenström macroglobulinemia. Literature overview and own experience].
    Adam Z; Pour L; Krejčí M; Ševčíková S; Pourová E; Ševčíková E; Král Z; Mayer J
    Vnitr Lek; 2016 Jan; 62(1):25-39. PubMed ID: 26967234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Waldenstrom macroglobulinemia: prognosis and management.
    Oza A; Rajkumar SV
    Blood Cancer J; 2015 Mar; 5(3):e394. PubMed ID: 25815903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Waldenström macroglobulinemia: 2017 update on diagnosis, risk stratification, and management.
    Gertz MA
    Am J Hematol; 2017 Feb; 92(2):209-217. PubMed ID: 28094456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Waldenström macroglobulinemia: 2012 update on diagnosis, risk stratification, and management.
    Gertz MA
    Am J Hematol; 2012 May; 87(5):503-10. PubMed ID: 22508368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How I treat Waldenström macroglobulinemia.
    Treon SP
    Blood; 2015 Aug; 126(6):721-32. PubMed ID: 26002963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN).
    Dimopoulos MA; García-Sanz R; Gavriatopoulou M; Morel P; Kyrtsonis MC; Michalis E; Kartasis Z; Leleu X; Palladini G; Tedeschi A; Gika D; Merlini G; Kastritis E; Sonneveld P
    Blood; 2013 Nov; 122(19):3276-82. PubMed ID: 24004667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Waldenström macroglobulinemia: 2023 update on diagnosis, risk stratification, and management.
    Gertz MA
    Am J Hematol; 2023 Feb; 98(2):348-358. PubMed ID: 36588395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Waldenström macroglobulinemia: 2013 update on diagnosis, risk stratification, and management.
    Gertz MA
    Am J Hematol; 2013 Aug; 88(8):703-11. PubMed ID: 23784973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simultaneous presentation of Waldenström macroglobulinemia and multiple myeloma: multidisciplinary diagnosis, treatment and 30-month follow-up.
    Carulli G; Ciancia EM; Azzarà A; Ottaviano V; Grassi S; Ciabatti E; Ferreri MI; Rocco M; Marini A; Petrini M
    J Clin Exp Hematop; 2013; 53(1):29-36. PubMed ID: 23801131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclophosphamide, bortezomib, and dexamethasone combination in waldenstrom macroglobulinemia.
    Leblebjian H; Noonan K; Paba-Prada C; Treon SP; Castillo JJ; Ghobrial IM
    Am J Hematol; 2015 Jun; 90(6):E122-3. PubMed ID: 25703132
    [No Abstract]   [Full Text] [Related]  

  • 15. Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016.
    Kapoor P; Ansell SM; Fonseca R; Chanan-Khan A; Kyle RA; Kumar SK; Mikhael JR; Witzig TE; Mauermann M; Dispenzieri A; Ailawadhi S; Stewart AK; Lacy MQ; Thompson CA; Buadi FK; Dingli D; Morice WG; Go RS; Jevremovic D; Sher T; King RL; Braggio E; Novak A; Roy V; Ketterling RP; Greipp PT; Grogan M; Micallef IN; Bergsagel PL; Colgan JP; Leung N; Gonsalves WI; Lin Y; Inwards DJ; Hayman SR; Nowakowski GS; Johnston PB; Russell SJ; Markovic SN; Zeldenrust SR; Hwa YL; Lust JA; Porrata LF; Habermann TM; Rajkumar SV; Gertz MA; Reeder CB
    JAMA Oncol; 2017 Sep; 3(9):1257-1265. PubMed ID: 28056114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180.
    Treon SP; Ioakimidis L; Soumerai JD; Patterson CJ; Sheehy P; Nelson M; Willen M; Matous J; Mattern J; Diener JG; Keogh GP; Myers TJ; Boral A; Birner A; Esseltine DL; Ghobrial IM
    J Clin Oncol; 2009 Aug; 27(23):3830-5. PubMed ID: 19506160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Waldenström macroglobulinemia: 2019 update on diagnosis, risk stratification, and management.
    Gertz MA
    Am J Hematol; 2019 Feb; 94(2):266-276. PubMed ID: 30328142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Waldenström macroglobulinemia: 2021 update on diagnosis, risk stratification, and management.
    Gertz MA
    Am J Hematol; 2021 Feb; 96(2):258-269. PubMed ID: 33368476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia.
    Dimopoulos MA; Gertz MA; Kastritis E; Garcia-Sanz R; Kimby EK; Leblond V; Fermand JP; Merlini G; Morel P; Morra E; Ocio EM; Owen R; Ghobrial IM; Seymour J; Kyle RA; Treon SP
    J Clin Oncol; 2009 Jan; 27(1):120-6. PubMed ID: 19047284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia.
    Ghobrial IM; Hong F; Padmanabhan S; Badros A; Rourke M; Leduc R; Chuma S; Kunsman J; Warren D; Harris B; Sam A; Anderson KC; Richardson PG; Treon SP; Weller E; Matous J
    J Clin Oncol; 2010 Mar; 28(8):1422-8. PubMed ID: 20142586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.